ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
6,114.63
-0.01%
Dow Jones
44,546.08
-0.37%
US Dollar vs MXN
20.3062
0.00%
Brent Oil
74.39
0.00%
Bitcoin
97,075.04
-0.53%
Pepperstone
Advertisement
Registration Strip Icon for monitor Monitoree múltiples cotizaciones en tiempo real de los principales intercambios, como la Bolsa de Valores de Londres, NASDAQ, NYSE, AMEX, Bovespa y más.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ

  6. Capricor Therapeutics Inc (CAPR) Cotización

Capricor Therapeutics Inc

Capricor Therapeutics Inc (CAPR)

Caprock Mining Corp
15.95
0.40
(2.57%)
Cerrado 16 Febrero 3:00PM
Delayed by 15 minutes
15.95
0.00
(0.00%)
Fuera de horario: 6:59PM
Delayed by 15 minutes

Su centro para precios en tiempo real, ideas y debates en vivo

Premium

Estadísticas y detalles clave

Último Precio
15.95
Postura de Compra
15.60
Postura de Venta
15.95
Volume Operado de la Acción
1,955,753
15.39 Rango del Día 16.2254
3.52 Rango de 52 semanas 23.40
Capitalización de Mercado [m]
725.245M
Precio Anterior
15.55
Precio de Apertura
15.54
Hora
50
@
15.98
Última hora de negociación
Volumen financiero
US$ 30,884,096
Precio Promedio Ponderado
15.7914
Volumen promedio (3 m)
1,151,400
Acciones en circulación
45,469,908
Rendimiento del Dividendo
-
Ratio Precio/Utilidad
-32.56
Beneficio por acción (BPA)
-0.49
turnover
25.18M
Beneficio neto
-22.29M

Acerca de Capricor Therapeutics Inc

Capricor Therapeutics, Inc. is a San Diego based biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases. Capricor's lead candidate, CAP-1002, is an allogeneic cardiac-derived cell t... Capricor Therapeutics, Inc. is a San Diego based biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases. Capricor's lead candidate, CAP-1002, is an allogeneic cardiac-derived cell therapy that is currently in late-stage clinical development for treating Duchenne muscular dystrophy (DMD). Capricor is also developing its exosome technology as a next-generation therapeutic platform. Capricor's proprietary StealthX¿ exosome platform has potential for a broad range of new therapeutic applications in the field of vaccinology as well as targeted oligonucleotide, protein and small molecule therapeutics to treat or prevent a variety of diseases. Mostrar más

Sector
Pharmaceutical Preparations
Industria
Pharmaceutical Preparations
Sitio web
www.capricor.com
Sede
Wilmington, Delaware, USA
Fundado
-
Capricor Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker CAPR. The last closing price for Capricor Therapeutics was US$15.55. Over the last year, Capricor Therapeutics shares have traded in a share price range of US$ 3.52 to US$ 23.40.

Capricor Therapeutics currently has 45,469,908 shares in issue. The market capitalisation of Capricor Therapeutics is US$707.06 million. Capricor Therapeutics has a price to earnings ratio (PE ratio) of -32.56.

Flujo de Opciones Capricor Therapeutics (CAPR)

Ver flujo de opciones completo

Flujo General

Optimista

Prima Neta

881k

Calls / Puts

450.00%

Comp. / Vent.

120.00%

OTM / ITM

120.00%

Sweeps Ratio

0.00%

CAPR Últimas noticias

Más noticias

Form S-8 - Securities to be offered to employees in employee benefit plans
Edgar (US Regulatory)
05 Febrero 2025
CAPR (2.57%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
06 Enero 2025
CAPR (2.57%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
06 Enero 2025
CAPR (2.57%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
06 Enero 2025
CAPR (2.57%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
06 Enero 2025
CAPR (2.57%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
06 Enero 2025
CAPR (2.57%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
06 Enero 2025
CAPR (2.57%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
06 Enero 2025
CAPR (2.57%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
06 Enero 2025
CAPR (2.57%)
Período †Variación(Ptos)Variación %AperturaPrecio MáximoPrecio MínimoAvg. Vol. diarioPrecio Promedio Ponderado
11.60511.188567445114.3451613.2299625614.4413622CS
42.3917.625368731613.561613.2277920014.51030781CS
12-1.89-10.594170403617.8420.7512.25115140014.66490715CS
2612.02305.8524173033.9323.43.79210583314.30852677CS
5212.13317.5392670163.8223.43.52124741412.89110813CS
15611.77281.5789473684.1823.42.6852301811.14301849CS
26014.571055.797101451.3823.40.889375447.83196382CS

CAPR - Preguntas Frecuentes

¿Cuál es el precio actual de las acciones de Capricor Therapeutics?
El precio actual de las acciones de Capricor Therapeutics es US$ 15.95
¿Cuántas acciones de Capricor Therapeutics están en circulación?
Capricor Therapeutics tiene 45,469,908 acciones en circulación
¿Cuál es la capitalización de mercado de Capricor Therapeutics?
La capitalización de mercado de Capricor Therapeutics es USD 707.06M
¿Cuál es el rango de negociación de 1 año para el precio de las acciones de Capricor Therapeutics?
Capricor Therapeutics ha negociado en un rango de US$ 3.52 a US$ 23.40 durante el último año
¿Cuál es el ratio PE (precio/beneficio) de Capricor Therapeutics?
El ratio precio/beneficio de Capricor Therapeutics es -32.56
¿Cuál es el ratio de efectivo a ventas de Capricor Therapeutics?
El ratio de efectivo a ventas de Capricor Therapeutics es 28.82
¿Cuál es la moneda de reporte de Capricor Therapeutics?
Capricor Therapeutics presenta sus resultados financieros en USD
¿Cuál es el último ingresos anual de Capricor Therapeutics?
El último ingresos anual de Capricor Therapeutics es USD 25.18M
¿Cuál es el último beneficio anual de Capricor Therapeutics?
El último beneficio anual de Capricor Therapeutics es USD -22.29M
¿Cuál es la dirección registrada de Capricor Therapeutics?
La dirección registrada de Capricor Therapeutics es 1209 ORANGE STREET, WILMINGTON, DELAWARE, 19801
¿Cuál es la dirección del sitio web de Capricor Therapeutics?
La dirección del sitio web de Capricor Therapeutics es www.capricor.com
¿En qué sector industrial opera Capricor Therapeutics?
Capricor Therapeutics opera en el sector PHARMACEUTICAL PREPARATIONS

Movimientos

Ver todo
  • Volumen
  • % Mayores Alzas
  • % Mayores Bajas
SímboloPrecioVol.
JTAIJet AI Inc
US$ 6.02
(133.33%)
104.48M
SRMSRM Entertainment Inc
US$ 0.6999
(95.50%)
254.39M
WRDWeRide Inc
US$ 31.4877
(83.39%)
21.07M
INLFINLIF Limited
US$ 16.27
(80.58%)
7.68M
MBRXMoleculin Biotech Inc
US$ 2.1201
(66.94%)
136.66M
BLACBellevue Life Sciences Acquisition Corporation
US$ 3.08
(-56.31%)
430.77k
BLACUBellevue Life Sciences Acquisition Corporation
US$ 3.36
(-52.68%)
5.21k
CSAICloudastructure Inc
US$ 19.0001
(-49.58%)
1.03M
NEXNNexxen International Ltd
US$ 10.30
(-49.16%)
164.82k
BSLKBolt Projects Holdings Inc
US$ 0.6626
(-46.13%)
13.4M
CNSPCNS Pharmaceuticals Inc
US$ 0.1415
(31.26%)
489.28M
MGOLMGO Global Inc
US$ 0.7176
(-15.08%)
417.31M
SRMSRM Entertainment Inc
US$ 0.6999
(95.50%)
254.39M
INTCIntel Corporation
US$ 23.60
(-2.20%)
230.26M
NVDANVIDIA Corporation
US$ 138.85
(2.63%)
194.99M

CAPR Discussion

Ver más
GreedyAgorist GreedyAgorist 4 días hace
Wow, I hardly ever perfectly time the bottom, but I sold a cash covered put today when it was red, and before I could second guess my play, it was green and up more than two bucks.

Any explanation for the 12% gain?

Oh, well, we were here ten days ago. Nothing to get excited about, right?
👍️0
Mr.Mister Mr.Mister 3 semanas hace
With BLA submission in late December, when would the FDA have to accept or reject their application by? Late February?
👍️0
Volcano Volcano 4 semanas hace
Breaking out now
Get ready for $70 upon FDA approval
💯 1 🔥 1
Volcano Volcano 1 mes hace
Price target $70-$100 upon FDA approval in a few months
Multi millionaire soon to be
👍 1
XWAVXALMIMAN XWAVXALMIMAN 1 mes hace
We got the news. We finished the submission and got $10 million. People are so impatient. I’ve waited 4 1/2 years. I can wait 6-9 months for approval. Families and patients should be pushing for a much quicker approval. 30-40 in 2025.
👍️0
D-bol D-bol 2 meses hace
Maybe news tomorrow
👍️0
MomsSpaghetti MomsSpaghetti 2 meses hace
My question to you CAPR folks who are likely more versed than I. Is after the submission is sent to FDA for approval (in your case Deramiocel (CAP-1002)) - How long does it take FDA to make a decision on average?

I am following another company MNMD that is in Phase 3 right now for LSD that got FDA Break Through Designation.
👍️0
GreedyAgorist GreedyAgorist 2 meses hace
Guess I was wrong about the new 5. It is not 20 or 17.50. Not yet. Those were the pump prices. If the pump is over for now, we might hang out around 12.50 for a while, making puts at 12.50 and 10 interesting. Likewise calls at 15 might be worth a shot. Although my next play is targeting March 17.50. If it gets there early, that will inform my next move.
👍️0
XWAVXALMIMAN XWAVXALMIMAN 2 meses hace
You’ll be sorry. Definitely an easy double from here within a year. I’ve held most shares for 4 1/2 years. Be patient. Linda sounded great - listened to interview last night after 12 days in Puerto Vallarta
👍️ 1
Laster Laster 2 meses hace
Got out yesterday afternoon before that huge dump.
It looked like it wanted to drop below $16.
Crazy AH trading down to $11 and back to $16.
Concern about one of their investigators.
Either way, I am out and hope others can make a better trade than I did. Now moving my money to other more quality stocks. JMO.
👍️0
D-bol D-bol 2 meses hace
What a day. Still not selling.
👍️0
PonkenPlonken PonkenPlonken 2 meses hace
RFK is irrelevant to how CAPR moves.

Everything is in the price here... plus a lot of birds in the bush. Why anyone would hold this stock AFTER it all happened, no catalyst on the horizeon. Presentation roadmap ends at "today".... is clear indication they know nothing will happen for a good year or two. So it will need a breather - which I believe you see in the chart.

Bios run towards events - not because of them.
GL
👍️0
Laster Laster 2 meses hace
Thank you. I have patience and can wait for mid 2025.
The problem is the biotech sector. It has gotten destroyed since Trump picked RFK Jr. as HHS secretary. Hopefully it will recover if RFK Jr. somehow doesn’t get the job.
Just hate the BS manipulation to drop stocks on no news. The stock market is a joke. Many Stocks now move on no news. I have seen stocks move from $1 to $10 on nothing. How is that possible or legal?
Just hope it doesn’t drop lower than $15. Then I might have to throw in the towel and move on.
👍️0
PonkenPlonken PonkenPlonken 2 meses hace
This stock trades on a lot of hopes, dreams and "ifs".
Not unlikely that whatever they announce, it will be a sell on news event.
It believe it has to cool off until the PDUFA which is ca 1 year away.
When the roadmap a company gives in their presentation ends with "today"...... is usually not a good sign. That is speaking in terms of PPS. For the company, everything is well and funding wont be an issue.
👍️0
Laster Laster 2 meses hace
Now down to $17.50. WOW. I can only guess people were expecting news on the BLA submission.
Maybe they are getting financing through the ATM and selling into the market.
Either way, this doesn't look good today.
👍️0
Laster Laster 2 meses hace
This stock is ridiculous. I don't know if it is manipulation or MMs getting the stop losses?
Opened at $19.44 and then in 1 minute it went to $20.75 and then the next minute it is down to $18.92.
Clearly, someone continues to keep this below $20. When will they be done????
This is criminal IMO. I am holding because I think it makes a run to $30 once all this crap is over.
MACD histogram on the daily is going to turn positive today.
JMO.
👍️0
Laster Laster 2 meses hace
The stock chart looks interesting. The MACD histogram is ready to turn positive.
The stock found support at the 25 day moving average.
PnF chart clearly shows double/triple top breakout past $21.
Nice flag forming. Needs volume to move past $20.
I think the stock will need BLA news to get the volume to move past $20.
I am looking for $30-$40 by mid 2025.

FYI. Conferences this week and next week.
Perfect time to release some updates.
👍 1
Laster Laster 3 meses hace
Well yesterday sucked. Moved BACK to $20 again only to get dumped back down to $19.
Looks like it will need significant volume to move back above $20.
2 conferences in early to mid December might help.
Happy Thanksgiving.
👍️0
Laster Laster 3 meses hace
I am looking for a firm break past $20 before end of the year.
I am hopeful for continued movement early 2025.
I like stocks that hold up well during sector selloff.
JMO.
👍️0
Laster Laster 3 meses hace
Holding up well in bad biotech market right now.
Break $20 and this could get Interesting.
👍️0
Mionaer1 Mionaer1 3 meses hace
https://d1io3yog0oux5.cloudfront.net/_a2273a855b16264d98c228e2a432c4ee/capricor/news/2024-11-20_Capricor_Therapeutics_Granted_Orphan_Drug_and_301.pdf

Great news.
👍️0
Mionaer1 Mionaer1 3 meses hace
Trading range $17-22 IMO. When BLA ready (end of 2024) $30 IMO.
👍️ 1
ed3/6me ed3/6me 3 meses hace
Thought it would've 17 so close. Only have pennies so can't buy much but figure the next level and 23/24. Down to 19/20 then bumping up past 30
👍 1
GreedyAgorist GreedyAgorist 3 meses hace
Looks like you nearly nailed that floor price.

So, the first reaction to the quarterly numbers makes sense: down on still no P/E ratio (i.e., negative earnings). And then a bounce, presumably thanks to bargain hunters who think that if 20 is a bargain, then 17 is a steal.

We seem to be settling in price-wise. It's not just FOMO* up like last month, although we can, with some regularity, still get 10-15% swings either way to keep it interesting. For options traders like me, who, before the FDA/BLA news, have been buying under 5 and selling covered calls (mostly at 5, with the occasional 7.5 thrown in there) the only question is: What is the new 5? 20 or 17.50?

*with a little BTFD mixed in
👍️0
Laster Laster 4 meses hace
Excellent that $21 support held. I was nervous for a little bit.
Now let’s break $22.50 so we can have clear sailing to $30 with target $35.
I am confident (sort of) that this will occur.
Here’s hoping.
👍 1
Laster Laster 4 meses hace
Failed $22.50 break multiple times.
Probably time to consolidate before next run.
Might drop and find support at $19.50.
Hopefully not.
Still looking and hoping for volume to power this past $22.50 for good.
👍️0
Laster Laster 4 meses hace
The stock chart is showing a nice ascending triangle from Sept 30th breakout from $10.
Using my novice chart skills, I get a target of $35 for the stock (flag pole from $10 to resistance at $22.50 = $12.50).
$22.50 plus $12.50 = $35. Sounds good to me.
Lower trendline has shown nice support but if the stock moves back to $20 then stock might drop back to $17.50.
Let’s what happens this week.
Hoping for move to $25 if the market looks good.
👍️0
staynafloat staynafloat 4 meses hace
I think what helped the most is that the OS is only 44.7 Mil. with that added in. It appears that a lot of traders are holding making it trade very thin.

LOL ... I've been waiting for almost 5 years for this to go thru all the trials and testing and it sure is sweet :)
👍️0
GreedyAgorist GreedyAgorist 4 meses hace
That dilution went about as well as any I’ve seen. The news did not even bring us below 18 for more than a wick or two. Correct me if I’m wrong, but the underwriters made out quite well, at least an extra dollar per additional share issued (~5M). Nice work if you can get it.
👍️0
Laster Laster 4 meses hace
Sounds good.
Hopefully yesterday was a technical sell off to show $20 support level.
Maybe get rid of those low hanging stop loss orders.
I am not worried about another financing so I expect a nice move to $25 then $30 by EOY.
Enjoy.
👍️0
XWAVXALMIMAN XWAVXALMIMAN 4 meses hace
No comment on Blackrock report owning over 5% of Capricor?
30 will be here soon. Maybe a short squeeze will pop us up to 40
👍️0
Laster Laster 4 meses hace
You never know but these $20 stocks tend to move to $25 or even $30.
I wouldn’t mind a nice 25% profit here.
👍️0
Volcano Volcano 4 meses hace
The small float is getting locked up by big boys everyday
My prediction $30 by Thanksgiving and $50 by Christmas and $100 upon FDA approval in early next year
Thus became the millionaire stock indeed
👍️0
Mionaer1 Mionaer1 4 meses hace
Piper Sandler PT $35

Piper Sandler analyst Edward Tenthoff initiates coverage on Capricor Therapeutics (NASDAQ: $CAPR) with an Overweight rating and a price target of $35.00.

The analyst comments: "Capricor is developing deramiocel (CAP-1002) to treat cardiomyopathy in Duchenne Muscular Dystrophy (DMD) boys. In the Phase II HOPE-2 trial (N=20), deramiocel slowed LVEF decline by 107% vs. placebo at 12 months. (p=0.002) At World Muscle Society, HOPE-2 OLE data showed deramiocel achieved an 8.1 point improvement in median LVEF and 11.0ml/m2 benefit in median End Systolic Volume vs. external controls at 2 years with benefit maintained out to 3 years. Capricor has begun the rolling BLA submission, and deramiocel could gain FDA approval for DMD cardiomyopathy in 2H:25. Deramiocel is partnered globally with Nippon Shinyaku with Capricor retaining 30-50% of potential blockbuster revenues, plus up to $1.5 billion in milestones. Capricor recently issued 5.1 million shares at $17 raising gross proceeds of $86 million, bringing pro forma cash to ~ $198 million excluding 3Q:24 burn."
👍️0
ed3/6me ed3/6me 4 meses hace
time will tell
👍️0
Mionaer1 Mionaer1 4 meses hace
$12? Never. $17 is the new floor IMO.
👍️0
ed3/6me ed3/6me 4 meses hace
My thought is slide back to 12-15 then move to 21-25. Dip again then about 20%up. Never straight unless flooring news
👍️0
Volcano Volcano 4 meses hace
This beast will keep moving up in the coming days
FDA approval is guaranteed and secured huge fund
I expect $50 by Christmas and $100 next year
I am a millionaire here
👍️0
GreedyAgorist GreedyAgorist 4 meses hace
Looks like they are not even asking enough for them.

"Capricor Therapeutics (CAPR) said Thursday that it priced an underwritten offering of about 4.4 million shares at $17 per share..."

I knew the dilution was coming. I guess I was hoping that news would be later, not this week. Like the earnings report that will be a negative number (but not as negative as last quarter).

Dips are buying opportunities, but when they are based on fundamental rules of supply and demand, I wonder if there is a hurry any more. Need to know what the new plateau is. Again, I guess it was too much to ask for that to be established after this week.

: - }
👍️0
XWAVXALMIMAN XWAVXALMIMAN 4 meses hace
It looked like we would hold at 20. Then they diluted our shares. I hate when that happens. Didn’t they have enough cash to survive until we would be profitable? Hopefully good news is coming and that extra money will be used for growth
👍️0
GreedyAgorist GreedyAgorist 4 meses hace
Arrgghh, they could not wait to dilute, huh? I just needed a couple more days.

Feels like somebody got the info early, too. I have to wonder what price they are getting. Today's high? The after hours' low?
👍️0
ed3/6me ed3/6me 4 meses hace
They sell today? Would be another k in your pocket
👍️0
XWAVXALMIMAN XWAVXALMIMAN 4 meses hace
Great day today. We started out down and then reversed and had trouble getting thru 20. Since I was having eye surgery today, I put in to sell 7250 shares at 20.20. It looked good for a while when we went down to low 19’s. I tried to buy back at 18.65 but never got there. This was my 3rd time selling and buying back and selling again. I’m done. Keeping my 40.000 shares until we get to 30-40.

We ran up to 23.40 before some profit taking. Some of you are looking for a 10% correction. I use Fibonacci numbers / Elliott Wave.
We went from 4 to 22 which is 18 and then went down to around 15; a 7 point retracement. 7/18 is around 38%.

Next Wave took us from 15 to 23+. Going up 8 points means that selling should take us down 3. Expect support at 20 before the next big up move.Have a great week. Let’s Go Mets and Guardians!
👍️0
D-bol D-bol 4 meses hace
DRUG We need a move like this one today!!
👍️0
D-bol D-bol 4 meses hace
I’m with you
👍️0
Volcano Volcano 4 meses hace
Yep
Still waiting for $100 Pps
👍️0
D-bol D-bol 4 meses hace
Volcano are you still here? Haven’t heard from you in a while.
👍️0
GreedyAgorist GreedyAgorist 4 meses hace
Just another day at the office with Capricor. Up 15%+ again. Do we get the 10% sell off before resuming the climb? That would still be a respectable gain of 7.5%. If we close above 22, that will be rarefied air for anyone in this for less than 6 years. Held the 21 handle briefly two weeks ago.

I have already played a couple of dips this week. Now waiting for a legitimate correction.
👍️0
XWAVXALMIMAN XWAVXALMIMAN 4 meses hace
Thanks Ed. I tried to sell 7250 at 19.80 which I had bought at 18.80. Still holding my 40,000 shares.
I’m buying some XRP with my profits and averaging down on some of my other losers. taking out some cash for vacations
👍️0
TechandBio TechandBio 4 meses hace
Next leg up will come in time patience!

$CAPR
👍️0

Su Consulta Reciente

NASDAQ
CAPR
Capricor Therapeutics
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2025 ADVFN PLC - Todos los derechos reservados

Quitar anuncios

Suscríbete a una experiencia sin publicidad

Sin anuncios

Pruébalo ahora

Mantenga los anuncios